Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie

Algonquin Power & Utilities

British American Tobacco

Cardinal Health

Canadian Imperial Bank of Commerce

Canadian Natural Resources

Chevron

Enbridge

Novartis

Pembina Pipeline

AT&T

TC Energy

Kiplinger "insights for investors" online, first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 5/25/21 revealed 13 yields ripe for picking. These International “Dividend Aristocrats,” have raised dividends at least five straight years (Canadian) 10 years (European Union) or 25 years (U.S. companies).

The 91 'Best Dividend Stocks On Earth' For June

GlaxoSmithKline

Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.

Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study

French pharmaceutical group Sanofi [s:fr: san] and U.K. drug company GlaxoSmithKline said they have begun global Phase 3 efficacy studies of their jointly produced COVID-19 candidate. The randomized, double-blind placebo controlled study will involve more than 35,000 volunteers aged 18 and older from the U.S., Africa, Asia and Latin America.

Sanofi and GlaxoSmithKline begin Phase 3 study of COVID-19 vaccine candidate

One part of the trial will test the vaccine against the South African variant of the virus.

New Covid-19 Vaccine Will Be Produced This Year As Sanofi, GSK Launch Phase 3 Trial

Production of the coronavirus vaccine developed by French firm Sanofi and GlaxoSmithKline (GSK) will begin within weeks, the firms have said.

Another COVID vaccine set to enter production within weeks - and UK has 60m doses ordered

Sanofi and GSK initiate global Phase 3 clin i cal efficacy study of COVID-19 vaccine candidate

Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate

First Busey

CNOOC

Donegal Group

FS KKR Capital Corp

Golub Capital BDC

Huntington Bancshares

Hercules Capital

Kenon Hlds

Oaktree Specialty Lending

Owl Rock Capital Corp

Piedmont Office Realty Trust

Sibanye Stillwater

Ternium

Umpqua Holdings

"Benjamin Graham Value Stocks match the criteria. Benjamin Graham followed." -YCharts Value Screener. These 35 Graham Formula Picks were screened by YCharts for revenue, assets, long-term debt, and EPS growth as of May 24, 2021, based on Graham's established criteria.

35 Graham Formula Value Dogs Sport 26 Ideal June Dividend Payers

Mexico Foreign Minister Marcel Ebrard said that the country would begin phase 3 trials for COVID-19 vaccines by Sanofi SA (NASDAQ: SNY) and China's Walvax soon. Mexico's health regulator Cofepris approved trials of the Sanofi vaccine, which uses a recombinant protein-based technology, Ebrard added, reports Reuters.

Sanofi, Walvax COVID-19 Vaccine Phase 3 Trials to Commence in Mexico: Reuters

Regeneron Pharmaceuticals

Regeneron (REGN) and Sanofi's (SNY) Libtayo gets positive CHMP opinion for two additional indications.

Regeneron (REGN)-Sanofi's Libtayo Gets Positive CHMP Opinion

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Libtayo (cemiplimab) as monotherapy in two advanced cancers. The CHMP recommended the approval of Libtayo for the first-line treatment of adults with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥50% of tumor cells with no EGFR, ALK, or ROS1 aberrations.

Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings

Expected approval of the COVID vaccine at the end of 2021 will allow the company to close the gap in multipliers compared to its closest competitors.

Sanofi: Underestimated Vaccine Potential

Sanofi SA (NASDAQ: SNY) revealed a new early peek at data from breast cancer candidate amcenestrant, an oral selective estrogen receptor degrader. Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Sanofi's Amcenestrant Combo Therapy Shows ORR of 34% In Breast Cancer Patients

These are two cheap stocks in an overvalued market.

Better Buy for 2021: GlaxoSmithKline or Sanofi?

Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting

Alkermes

Biogen

Bristol-Myers

Blueprint Medicines

Myovant Sciences

Provention Bio Inc

Vertex Pharmaceuticals

Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.

8 Biotech Stocks With Major Catalysts on the Horizon

Sanofi has increased its annual payout by 12%+. Compared to historic trends, this increase is way above normal.

Sanofi: Evaluating The Recent Dividend Hike

Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.

Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon

Sanofi (EPA: SAN) said on Monday its candidate COVID-19 vaccine that it developed with Britain's GlaxoSmithKline (LON: GSK) showed promising results in early-stage clinical trials, paving the way to move ahead with a late-stage trial. Sanofi said: “The Phase II interim results showed 95% to 100% seroconversion following a second injection in all age groups […] The post Sanofi releases vaccine study results, Dr Gottlieb comments on mask-wearing appeared first on Invezz.

Sanofi releases vaccine study results, Dr Gottlieb comments on mask-wearing

Yet competition with Pfizer and Moderna could still be stiff.

Sanofi Executives Say Covid Vaccine Could Be 'Universal Booster'

GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market reaction despite posting positive mid-stage trial results for their COVID-19 vaccine.

GSK and Sanofi look to catch up in vaccine race with booster doses

GlaxoSmithKline and Sanofi plan to join vaccine race with booster doses

A Phase 3 trial to test the vaccine's efficacy is expected to start in a matter of weeks, with the vaccine showing potential to be a booster shot.

Sanofi, GSK Covid Vaccine Triggers ‘Strong Immune Response' As Firms Aim For Approval Later This Year

Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of their COVID-19 vaccine, raising hopes it could join the fight against the pandemic. The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.

Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study

News will offer some some relief for GSK chief Emma Walmsley, who has been under pressure from investor

GlaxoSmithKline and Sanofi report strong results in trials of Covid vaccine

GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion following a second injection in all age groups, with acceptable tolerability and with no safety concerns.

News for Sanofi Stock (SNY)